Is Curis (CRIS) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Curis (CRIS) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Curis is one of 842 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CRIS is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CRIS's full-year earnings has moved 38.24% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that CRIS has returned about 56.57% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 1.62% on average. This means that Curis is performing better than its sector in terms of year-to-date returns.
Looking more specifically, CRIS belongs to the Medical - Biomedical and Genetics industry, which includes 345 individual stocks and currently sits at #58 in the Zacks Industry Rank. On average, stocks in this group have gained 9.77% this year, meaning that CRIS is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CRIS. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Curis, Inc. (CRIS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
